HCPCS Level II code C9783 designates a blinded transcatheter procedure for implantation of a coronary sinus reduction device or a placebo control within an approved investigational device exemption (IDE) study. The code packages vascular access and closure, right heart catheterization, venous and coronary sinus angiography, and any imaging guidance, supervision, and interpretation performed under the IDE protocol. This code matters because it standardizes reporting for investigational transcatheter cardiac procedures that evaluate novel therapies to treat conditions involving the coronary sinus, supporting clinical trials, regulatory oversight, and national utilization tracking.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and typical settings of care, plus what to expect in benchmarking and policy review sections: national utilization benchmarks where available, payer coverage trends and coding guidance relevant to IDE studies, and the clinical workflow elements reflected in the code. The publication also summarizes implications for billing and claims processing when procedures are performed as part of approved investigational studies.

Data not provided in the input: specific associated taxonomies, ICD-10 diagnosis mappings, related billing codes, and payer-specific reimbursement rates.